Sonorx

   
Google
 
Web NewDrugInformation.com

Sonorx


Drug - Sonorx
The trade name of the product as shown on the labeling.

Dosage - SUSPENSION; ORAL
The product dosage form and route separated by a semi-colon.

Active Ingredient(s) - Simethicone-cellulose
Multiple ingredients are in alphabetical order.

Strength - 7.5MG/ML
The potency of the active ingredient(s), Simethicone-cellulose. May repeat for multiple part products.

Applicant - BRACCO
The firm name holding legal responsibility for Sonorx. The firm name is condensed to a maximum twenty character unique string.

New Drug Application (NDA) Number - 020773
The FDA assigned number to Sonorx. Format is nnnnnn.

Product Number - 001
The FDA assigned number to identify Sonorx. Each strength is a separate product. May repeat for multiple part products. Format is nnn.

Therapeutic Equivalence (TE) Code -
The TE Code indicates the therapeutic equivalence rating of generic to innovator Rx products.

Approval Date - Oct 29, 1998
The date Sonorx was approved as stated in the FDA approval letter to the applicant. The format is Mmm dd, yyyy. Products approved prior to the January 1, 1982 contain the phrase: "Approved prior to Jan 1, 1982".

Reference Listed Drug (RLD) - No
The pioneer or innovator of Sonorx. The RLD identifies the product Abbreviated New Drug Applications (ANDA) use as a reference. Format is Yes or No.

Type - DISCN
The group or category of approved drugs Sonorx is in. Format is RX, OTC, DISCN.

Applicant Full Name - Bracco Diagnostics Inc
The full name of the firm holding legal responsibility for the new application of Sonorx.

Sonorx